BMRA vs XBIO

The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.

XBIO exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in fundamental health. While the company maintains a strong liquidity position with a Current Ratio of 8.32 and zero debt, it suffers from extreme operational inefficiency with a profit margin of -90.07%. Despite recent earnings beats and modest revenue growth, the technical trend is completely bearish (0/100) and the long-term price performance is devastating (-84.6% over 5 years). The company remains a high-risk speculative play dependent on future drug candidate success rather than current financial strength.